AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12575340 — intervention group
Group type: COMPARATOR
Intervention: Cataract extraction combined with IOL implantation through conventional large incision
Number of subjects: 93
Study 9649038 — intervention group
Group type: EXPERIMENTAL
Intervention: Needlescopic cholecystectomy
Number of subjects: 60
Study 9649038 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 60
Study 8018766 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (alpha n-1 IFN) treatment at a dosage of 3 MU/day subcutaneously for 5 months
Number of subjects: 22
Study 8018766 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy alone
Number of subjects: 22
Study 3069178 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage of axillary wounds after surgery for breast cancer
Number of subjects: 0
Study 3069178 — intervention group
Group type: COMPARATOR
Intervention: Omission of suction drainage
Number of subjects: 0
Study 31721277 — intervention group
Group type: EXPERIMENTAL
Intervention: Otaplimastat 80 mg (administered twice daily for 3 days)
Number of subjects: 80
Study 31721277 — intervention group
Group type: EXPERIMENTAL
Intervention: Otaplimastat 40 mg
Number of subjects: 80
Study 31721277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31721277 — intervention group
Group type: EXPERIMENTAL
Intervention: Otaplimastat 80 mg
Number of subjects: 80
Study 30627738 — intervention group
Group type: EXPERIMENTAL
Intervention: C‑MAC D‑Blade®
Number of subjects: 52
Study 30627738 — intervention group
Group type: COMPARATOR
Intervention: LMA Fastrach®
Number of subjects: 52
Study 28455423 — intervention group
Group type: COMPARATOR
Intervention: Care staff assessments
Number of subjects: 556
Study 25282145 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodSwings Plus (MS-Plus)
Number of subjects: 156
Study 25282145 — intervention group
Group type: COMPARATOR
Intervention: MoodSwings (MS)
Number of subjects: 156
Study 22398880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 104
Study 22398880 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT)
Number of subjects: 104
Study 22398880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 104
Study 22398880 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 104
Study 19684384 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.d.
Number of subjects: 15
Study 19684384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18556803 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP)
Number of subjects: 60
Study 18556803 — intervention group
Group type: COMPARATOR
Intervention: Control (upright position)
Number of subjects: 60
Study 15942770 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged group (40-50 years)
Number of subjects: 73
Study 15942770 — intervention group
Group type: COMPARATOR
Intervention: Old-aged group (60-70 years)
Number of subjects: 73
Study 11832440 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin stimulation
Number of subjects: 22
Study 11832440 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin stimulation
Number of subjects: 22
Study 11832440 — intervention group
Group type: COMPARATOR
Intervention: Insulin and pentagastrin
Number of subjects: 22
Study 10412851 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg amoxicillin plus 125 mg clavulanic acid (Augmentin), every 8 h for 10 days
Number of subjects: 21
Study 10412851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7751850 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 7751850 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and aggressive management of modifiable risk factors
Number of subjects: 0
Study 2321778 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine with 5 micrograms/ml fentanyl
Number of subjects: 100
Study 2321778 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of 0.25% bupivacaine with 5 micrograms/ml fentanyl plus 3.33 micrograms/ml epinephrine
Number of subjects: 100
Study 2321778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine test dose
Number of subjects: 100
Study 2321778 — intervention group
Group type: COMPARATOR
Intervention: 2-chloroprocaine test dose
Number of subjects: 100
Study 7192498 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum antibodies to cow milk proteins
Number of subjects: 50
Study 7192498 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum antibodies to soy protein
Number of subjects: 50
Study 7192498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk and soy formulae fed from birth until 4 months of age
Number of subjects: 50
Study 31921170 — intervention group
Group type: EXPERIMENTAL
Intervention: GTU®MultiHIV DNA vaccine delivered by transcutaneous (TC) and intramuscular (IM) injection
Number of subjects: 0
Study 31921170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30225882 — intervention group
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate
Number of subjects: 0
Study 30225882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26930159 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min B‐SES training at 3‐4 METs for four weeks
Number of subjects: 19
Study 25439415 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine 1 mg/kg
Number of subjects: 66
Study 25439415 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural lidocaine (1.5% lidocaine)
Number of subjects: 66
Study 25439415 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural lidocaine (1.5% lidocaine)
Number of subjects: 66
Study 25439415 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (control)
Number of subjects: 66
Study 23213984 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion group (n=26)
Number of subjects: 52
Study 23213984 — intervention group
Group type: COMPARATOR
Intervention: Western medication group (n=26)
Number of subjects: 52
Study 20371164 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alanyl-glutamine (l-Ala-Gln)
Number of subjects: 32
Study 20371164 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 32
Study 17582745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure
Number of subjects: 2
Study 17582745 — intervention group
Group type: COMPARATOR
Intervention: Dim light exposure
Number of subjects: 2
Study 17582745 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 2
Study 15733013 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin for 48 weeks
Number of subjects: 491
Study 15733013 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin for 24 weeks
Number of subjects: 491
Study 15733013 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin for 48 weeks in HCV genotype 1
Number of subjects: 491
Study 15733013 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin for 24 weeks in HCV genotype 1
Number of subjects: 491
Study 15733013 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin for 48 weeks in HCV genotypes 2 or 3
Number of subjects: 491
Study 15733013 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon α‐2a (40KD) plus ribavirin
Number of subjects: 491
Study 15733013 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 491
Study 12419718 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation in elderly patients
Number of subjects: 30
Study 12419718 — intervention group
Group type: COMPARATOR
Intervention: Propofol sedation in younger patients
Number of subjects: 30
Study 12419718 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery of psychomotor function in elderly patients
Number of subjects: 30
Study 10360852 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30
Study 10360852 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 30
Study 7719880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bricanyl Turbuhaler (terbutaline sulphate 0.5 mg t.i.d.)
Number of subjects: 20
Study 7719880 — intervention group
Group type: COMPARATOR
Intervention: Ventolin Rotahaler (salbutamol 0.4 mg t.i.d.)
Number of subjects: 20
Study 2126657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg after cord clamping
Number of subjects: 201
Study 2126657 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic prophylaxis)
Number of subjects: 201
Study 7341284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 28
Study 7341284 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 28
Study 7341284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol and Metoprolol (combined with thiazide diuretic)
Number of subjects: 28
Study 7341284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol and Metoprolol
Number of subjects: 28
Study 31781822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocontraction group
Number of subjects: 3
Study 31781822 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraction group
Number of subjects: 3
Study 31781822 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 29571566 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange Juice (OJ)
Number of subjects: 26
Study 29571566 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-free Cola
Number of subjects: 26
Study 29029639 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at ST36 (single acupoint)
Number of subjects: 0
Study 29029639 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at CV12 (single acupoint)
Number of subjects: 0
Study 29029639 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at ST36-CV12 (matching acupoints)
Number of subjects: 0
Study 29029639 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25656999 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut sublingual immunotherapy (SLIT)
Number of subjects: 40
Study 24724774 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein as a replacement for other sources of calories (WPR)
Number of subjects: 626
Study 24724774 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein as a supplement without dietary modification (WPS)
Number of subjects: 626
Study 24724774 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein with resistance exercise
Number of subjects: 626
Study 24724774 — intervention group
Group type: COMPARATOR
Intervention: Whey Protein compared with carbohydrates
Number of subjects: 626
Study 24724774 — intervention group
Group type: COMPARATOR
Intervention: Whey Protein compared with protein sources other than whey
Number of subjects: 626
Study 22494623 — intervention group
Group type: EXPERIMENTAL
Intervention: L-BLP25
Number of subjects: 159
Study 22494623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 19397502 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml 0.5% bupivacaine
Number of subjects: 29
Study 19397502 — intervention group
Group type: COMPARATOR
Intervention: 10 ml 0.25% bupivacaine
Number of subjects: 29
Study 20193521 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training at 20% of maximal intensity
Number of subjects: 60
Study 20193521 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training at 60% of maximal intensity
Number of subjects: 60
Study 20193521 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study 16170977 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine/2.5% prilocaine (L/P)
Number of subjects: 40
Study 16170977 — intervention group
Group type: COMPARATOR
Intervention: 20% benzocaine (Topex)
Number of subjects: 40
Study 12240780 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg PO or IV q24h
Number of subjects: 236
Study 12240780 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin 500 mg IV q24h for > or = 2 days plus ceftriaxone 1 g IV q24h for 2 days
Number of subjects: 236
Study 10422936 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine/glycopyrrolate (0.05/0.01 mg/kg)
Number of subjects: 16
Study 10422936 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 16
Study 10422936 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 16
Study 7818126 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 L unhumidified O2 via nasal cannula
Number of subjects: 293
Study 7818126 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% oxygen by face tent
Number of subjects: 293
Study 7818126 — intervention group
Group type: COMPARATOR
Intervention: Nurse‐coached lung hyperinflations
Number of subjects: 293
Study 7818126 — intervention group
Group type: COMPARATOR
Intervention: No oxygen enhancing regimen
Number of subjects: 293
Study 2204260 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil 300 mg/day (TT group)
Number of subjects: 140
Study 2204260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PP group)
Number of subjects: 140
Study 728894 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC-levamisole (LSM)
Number of subjects: 114
Study 728894 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC-BCG-LMS
Number of subjects: 114
Study 728894 — intervention group
Group type: COMPARATOR
Intervention: FAC chemotherapy alone
Number of subjects: 114
Study 30113728 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient consultation
Number of subjects: 314639
Study 30113728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 314639
Study 28545758 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect Management (AM) intervention
Number of subjects: 377
Study 28545758 — intervention group
Group type: COMPARATOR
Intervention: Standard skills-based HIV prevention intervention (SB)
Number of subjects: 377
Study 28545758 — intervention group
Group type: COMPARATOR
Intervention: General health promotion intervention (HP)
Number of subjects: 377
Study 25873349 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached Care intervention visit with EMPATHy software toolkit
Number of subjects: 190
Study 25873349 — intervention group
Group type: COMPARATOR
Intervention: Coached Care intervention visit without software tools
Number of subjects: 190
Study 23424215 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine at 250 mg day(-1)
Number of subjects: 50
Study 23424215 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAA at 50 mg day(-1)
Number of subjects: 50
Study 23424215 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine at 250 mg day(-1) + DMAA at 50 mg day(-1)
Number of subjects: 50
Study 23424215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21376643 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded PTFE grafts (Hb-PTFE)
Number of subjects: 569
Study 21376643 — intervention group
Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 569
Study 19304089 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mitomycin-C (MMC) 0.2 mg/mL applied for 45 seconds after PRK
Number of subjects: 179
Study 19304089 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 179
Study 19304089 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mitomycin-C (MMC)
Number of subjects: 179
Study 17526168 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 60
Study 17526168 — intervention group
Group type: COMPARATOR
Intervention: Methycbal (Mecolbalamin) administration
Number of subjects: 60
Study 15225586 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackcurrant juice (475 to 1000ml/d)
Number of subjects: 57
Study 15225586 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin drink (475 to 1000ml/d)
Number of subjects: 57
Study 15225586 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 57
Study 11495222 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 142
Study 11495222 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood (control)
Number of subjects: 142
Study 10682136 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 20 mg twice daily
Number of subjects: 35
Study 10682136 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg twice daily
Number of subjects: 35
Study 10682136 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (both doses)
Number of subjects: 35
Study 10682136 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (previously used)
Number of subjects: 35
Study 8313315 — intervention group
Group type: EXPERIMENTAL
Intervention: FUDR (0.3 mg/kg/day) and leucovorin (30 mg/m2/day) as a 14‐day continuous infusion through an implantable hepatic arterial pump alternating with a 4‐week rest period (Group D)
Number of subjects: 42
Study 8313315 — intervention group
Group type: EXPERIMENTAL
Intervention: FUDR (0.25 mg/kg/day) and leucovorin (30 mg/m2/day) as a 14‐day infusion alternating with 2 weeks of saline (Group E)
Number of subjects: 42
Study 8313315 — intervention group
Group type: EXPERIMENTAL
Intervention: FUDR (0.3 mg/kg/day) with leucovorin (15 mg/m2/day) for 2 weeks followed by a 2‐week rest (Group F)
Number of subjects: 42
Study 8313315 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial chemotherapy with FUDR and leucovorin
Number of subjects: 42
Study 8313315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose of leucovorin (15 mg/m2) with FUDR
Number of subjects: 42
Study 3042310 — intervention group
Group type: EXPERIMENTAL
Intervention: BAYm 1099 (50 mg 3 times/day)
Number of subjects: 15
Study 3042310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31556655 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 82
Study 31556655 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 82
Study 31556655 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychodynamic therapy (SPT)
Number of subjects: 82
Study 28544774 — intervention group
Group type: COMPARATOR
Intervention: Hetrombopag (5 mg, 10 mg, 20 mg, 30 mg, 40 mg single dose)
Number of subjects: 72
Study 28544774 — intervention group
Group type: COMPARATOR
Intervention: Hetrombopag (2.5 mg, 5.0 mg, 7.5 mg once daily for 10 days)
Number of subjects: 72
Study 25387127 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Drink (ED)
Number of subjects: 19
Study 25387127 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study 25387127 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 19
Study 25387127 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (ED, PL, CTL)
Number of subjects: 19
Study 23313564 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg
Number of subjects: 168
Study 23313564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 23313564 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine or Placebo
Number of subjects: 168
Study 22004303 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated outpatient cognitive‐behavioral intervention for co‐occurring AOD and suicidality (I‐CBT)
Number of subjects: 40
Study 22004303 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (E‐TAU)
Number of subjects: 40
Study 18665686 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and Media Literacy (CML)
Number of subjects: 90
Study 18665686 — intervention group
Group type: COMPARATOR
Intervention: Discussion as Usual (DAU)
Number of subjects: 90
Study 15975966 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneous injection, twice weekly for three months)
Number of subjects: 90
Study 15975966 — intervention group
Group type: COMPARATOR
Intervention: DMARDs alone (control group)
Number of subjects: 90
Study 12883465 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal ACY gel (LAG) applied five times daily for up to eight weeks
Number of subjects: 26
Study 12883465 — intervention group
Group type: COMPARATOR
Intervention: Plain ACY gel (PAG)
Number of subjects: 26
Study 10856268 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg omapatrilat
Number of subjects: 9
Study 10856268 — intervention group
Group type: COMPARATOR
Intervention: 20 mg fosinopril
Number of subjects: 9
Study 9379646 — intervention group
Group type: EXPERIMENTAL
Intervention: P III NP in patients with POAG
Number of subjects: 30
Study 9379646 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study 9379646 — intervention group
Group type: EXPERIMENTAL
Intervention: P I CP in patients with POAG
Number of subjects: 30
Study 8409505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 25
Study 8409505 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 25
Study 2428668 — intervention group
Group type: EXPERIMENTAL
Intervention: VBM plus 5‐fluorouracil
Number of subjects: 267
Study 2428668 — intervention group
Group type: COMPARATOR
Intervention: VBM
Number of subjects: 267
Study 2428668 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous chemotherapy
Number of subjects: 267
Study 2428668 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 267
Study 31280100 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 75
Study 31280100 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (PVB)
Number of subjects: 75
Study 31280100 — intervention group
Group type: COMPARATOR
Intervention: Control group (IV-morphine)
Number of subjects: 75
Study 29902697 — intervention group
Group type: EXPERIMENTAL
Intervention: Learn to be safe with Emmy and friends™
Number of subjects: 611
Study 29902697 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 611